Key facts
- This page summarizes Derrell Porter's Form 4 filing for Acumen Pharmaceuticals, Inc. (ABOS).
- 7 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Jun 2026, 17:10.
Derrell Porter - 15 Jun 2026 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)
- Reporting relationship
- Director
- Issuer ticker
- ABOS
- Reported as of
- 15 Jun 2026
- Net transaction value
- -$75,240
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2026, 17:10:15 UTC
- Prior SEC filing
- 05 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Derek Meisner, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Derrell Porter filed Form 4 for Acumen Pharmaceuticals, Inc. (ABOS) on 17 Jun 2026.
Change
- Previous filing in this sequence was filed on 05 Jun 2026.
- Current net transaction value: -$75,240.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001706400
Primary reporting owner
Porter Derrell
- Relationship
- Director
- Address
- C/O ACUMEN PHARMACEUTICALS, INC., 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON
- Signature
- /s/ Derek Meisner, Attorney-in-Fact
- Signature date
- 17 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABOS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +6,460
- Change %
- +13%
- Price
- $1.07*
- Shares after
- 54,760
- Date
- 15 Jun 2026
- Ownership
- Direct
ABOS
transaction
Common Stock
Sale
- Transaction value
- $15,149
- Shares
- -6,460
- Change %
- -12%
- Price
- $2.34
- Shares after
- 48,300
- Date
- 15 Jun 2026
- Ownership
- Direct
ABOS
transaction
Common Stock
Sale
- Transaction value
- $29,773
- Shares
- -12,800
- Change %
- -27%
- Price
- $2.33
- Shares after
- 35,500
- Date
- 16 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
ABOS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +13,040
- Change %
- +37%
- Price
- $1.07*
- Shares after
- 48,540
- Date
- 17 Jun 2026
- Ownership
- Direct
ABOS
transaction
Common Stock
Sale
- Transaction value
- $30,318
- Shares
- -13,040
- Change %
- -27%
- Price
- $2.32
- Shares after
- 35,500
- Date
- 17 Jun 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABOS
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -6,460
- Change %
- -33%
- Price
- $0.000000*
- Shares after
- 13,040
- Date
- 15 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,460
- Exercise price
- $1.07
- Footnotes
- F2
ABOS
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -13,040
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,040
- Exercise price
- $1.07
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.305 to $2.345. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The shares subject to the option vested in full on the date of the 2026 annual stockholder meeting.